Abbott India Limited (NSE:ABBOTINDIA)
India
· Delayed Price · Currency is INR 35,670
+730 (2.09%)
Jun 30, 2025, 3:30 PM IST
Abbott India Revenue
In the fiscal year ending March 31, 2025, Abbott India had annual revenue of 64.09B INR with 9.58% growth. Abbott India had revenue of 16.05B in the quarter ending March 31, 2025, with 11.54% growth.
Revenue
64.09B
Revenue Growth
+9.58%
P/S Ratio
11.61
Revenue / Employee
16.80M
Employees
3,814
Market Cap
743.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 64.09B | 5.60B | 9.58% |
| Mar 31, 2024 | 58.49B | 5.00B | 9.35% |
| Mar 31, 2023 | 53.49B | 4.35B | 8.86% |
| Mar 31, 2022 | 49.13B | 6.03B | 14.00% |
| Mar 31, 2021 | 43.10B | 2.17B | 5.30% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
Abbott India News
- 5 months ago - Abbott India shares surge 3% as net profit jumps 16% YoY to Rs 360.8 crore in Q3 - Business Upturn
- 5 months ago - Pharma stocks: Glenmark up 1.57%, Glaxo gains 1.31%, Mankind Pharma declines 2.84% - Business Upturn
- 5 months ago - Pharma Stocks Today: Biocon surges 4.41%, Mankind Pharma up 1.85%; Glaxo and Abbott India decline - Business Upturn
- 6 months ago - Stock Market Update, January 7: Apollo Hospitals, Apar Industries, Abbott India, Amber Enterprises and more hit 52-week highs today - Business Upturn
- 7 months ago - Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27% - Business Upturn
- 7 months ago - Abbott India launches 14-Valent Pneumococcal Conjugate vaccine offering broad protection for children - Business Upturn
- 8 months ago - Abbott India shares fall nearly 4% following Q2 results - Business Upturn
- 8 months ago - Abbott India Q2 FY25 Results: Revenue up 9.3% YoY to ₹1,632.67 crore, Net Profit rises 14.6% YoY - Business Upturn